120 related articles for article (PubMed ID: 23984921)
1. The next 10 years in personalized medicine in cardiology.
Tantry US; Gurbel PA
Expert Rev Cardiovasc Ther; 2013 Aug; 11(8):933-5. PubMed ID: 23984921
[No Abstract] [Full Text] [Related]
2. Best medical intervention for arterial disease or wishful thinking.
Abbott A
Eur J Vasc Endovasc Surg; 2011 Apr; 41(4):509-10. PubMed ID: 21285001
[No Abstract] [Full Text] [Related]
3. Comments regarding 'Best medical therapy or wishful thinking in carotid disease? a single centre audit in Germany'.
Milner R
Eur J Vasc Endovasc Surg; 2011 Apr; 41(4):507-8. PubMed ID: 21256775
[No Abstract] [Full Text] [Related]
4. [Pharmacological prevention of cardiovascular diseases].
Okovityĭ SV; Kulikov AN; Shulenin KS
Eksp Klin Farmakol; 2011; 74(11):43-7. PubMed ID: 22288160
[TBL] [Abstract][Full Text] [Related]
5. Personalized vascular medicine: individualizing drug therapy.
Degoma EM; Rivera G; Lilly SM; Usman MH; Mohler ER
Vasc Med; 2011 Oct; 16(5):391-404. PubMed ID: 22003003
[TBL] [Abstract][Full Text] [Related]
6. Most people don't take heart drugs as directed.
Harv Mens Health Watch; 2012 Nov; 17(4):1, 8. PubMed ID: 23330206
[No Abstract] [Full Text] [Related]
7. [Personalized medicine in cardiology?].
Kroemer HK; Hasenfuß G
Herz; 2014 Mar; 39(2):177. PubMed ID: 24623569
[No Abstract] [Full Text] [Related]
8. Cardiovascular pharmacogenetics of antihypertensive and lipid- lowering therapies.
Vanichakarn P; Hwa J; Stitham J
Curr Mol Med; 2014; 14(7):849-79. PubMed ID: 25109793
[TBL] [Abstract][Full Text] [Related]
9. Prospects of personalized medicine in cardiovascular diseases.
Lenfant C
Metabolism; 2013 Jan; 62 Suppl 1():S6-10. PubMed ID: 22999711
[TBL] [Abstract][Full Text] [Related]
10. Best medical therapy or wishful thinking in carotid disease? A single-centre audit in Germany.
Lutz HJ; Sacuiu RD; Gahl B; Savolainen H
Eur J Vasc Endovasc Surg; 2011 Apr; 41(4):501-6. PubMed ID: 21295500
[TBL] [Abstract][Full Text] [Related]
11. Differences in management and outcomes between male and female patients with atherothrombotic disease: results from the REACH Registry in Europe.
Morrell J; Zeymer U; Baumgartner I; Limbourg T; Röther J; Bhatt DL; Steg PG;
Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):270-7. PubMed ID: 20606595
[TBL] [Abstract][Full Text] [Related]
12. Regarding "Pharmacologic risk factor management in peripheral arterial disease: a vade mecum for vascular surgeons".
Paraskevas KI
J Vasc Surg; 2008 Sep; 48(3):776-7; author reply 777. PubMed ID: 18727983
[No Abstract] [Full Text] [Related]
13. [Summary of the multidisciplinary guideline on cardiovascular risk management (revision 2011)].
Wiersma T; Smulders YM; Stehouwer CD; Konings KT; Lanphen J
Ned Tijdschr Geneeskd; 2012; 156(36):A5104. PubMed ID: 22951134
[TBL] [Abstract][Full Text] [Related]
14. Guidelines for a new year.
Somberg JC
Am J Ther; 2014; 21(1):1. PubMed ID: 24401701
[No Abstract] [Full Text] [Related]
15. Comprehensive medical management of peripheral arterial disease.
Gandhi S; Weinberg I; Margey R; Jaff MR
Prog Cardiovasc Dis; 2011; 54(1):2-13. PubMed ID: 21722781
[TBL] [Abstract][Full Text] [Related]
16. [New cardiovascular-active drugs].
Bölter C
Z Arztl Fortbild (Jena); 1984; 78(19):797-800. PubMed ID: 6506791
[No Abstract] [Full Text] [Related]
17. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries.
Kotseva K; Wood D; De Backer G; De Bacquer D; Pyörälä K; Reiner Z; Keil U;
Eur J Cardiovasc Prev Rehabil; 2010 Oct; 17(5):530-40. PubMed ID: 20577089
[TBL] [Abstract][Full Text] [Related]
18. Recommendations of the second Indo-U.S. health summit on prevention and control of cardiovascular disease among Asian Indians.
Enas EA; Singh V; Munjal YP; Gupta R; Patel KC; Bhandari S; Agarwal AK; Joshi SR; Anoop M; Prabhakaran D; Shah B; Reddy S; Sharma B; Trehan N; Yavagal ST; Kasliwal RR;
Indian Heart J; 2009; 61(3):265-74. PubMed ID: 20503833
[No Abstract] [Full Text] [Related]
19. Interest of the National Heart Institute in comparative pharmacology.
Stengle JM
Fed Proc; 1967; 26(4):1162-3. PubMed ID: 6028778
[No Abstract] [Full Text] [Related]
20. Incorporation of economic evidence in the Dutch guideline 'cardiovascular risk management'.
Tan SS; Rutten FF; Hakkaart-van Roijen L
J Eval Clin Pract; 2011 Dec; 17(6):1094-101. PubMed ID: 21040249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
